Previous 10 | Next 10 |
TEL AVIV, Israel, Nov. 15, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd . (Nasdaq: PRFX) (" PainReform " or the " Company "), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a business update for the third quarter e...
Odyssey Marine Exploration Inc. (OMEX) is expected to report for quarter end 2023-06-30 The Very Good Food Company Inc. (VGFCQ) is expected to report for quarter end 2023-06-30 SeaChange International Inc. (SEAC) is expected to report for Q1 2024 Allena Pharmaceuticals Inc. (ALNAQ) is...
QualTek Services Inc. (QTEKQ) is expected to report for Q2 2023 Amerityre Corp (AMTY) is expected to report for quarter end 2023-06-30 BYD Co - Class H (BYDDF) is expected to report for quarter end 2023-06-30 Shionogi & Co. Ltd. ADR (SGIOY) is expected to report for Q1 2024 Ea...
Zovio Inc. (ZVOI) is expected to report for quarter end 2023-06-30 Sierra Grande Minerals Inc Ordinary Shares (SIERD) is expected to report for quarter end 2023-06-30 The Intergroup Corporation (INTG) is expected to report for Q1 2024 Fortescue Metals Group Ltd ADR (FSUGY) is expected...
Targeting to commence second part of Phase 3 clinical trial in mid-Q4 2023 Trial completion and results expected in mid-2024 TEL AVIV, Israel, Sept. 11, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd . (Nasdaq: PRFX) (" PainReform " or the " Company "), a clinical-stage speci...
Blue Water Biotech Inc. (BWV) is expected to report $-0.12 for Q2 2023 Lycos Energy Inc (MAAL) is expected to report for quarter end 2023-06-30 Esports Entertainment Group Inc. (GMBL) is expected to report $-2.92 for Q4 2023 SigmaTron International Inc. (SGMA) is expected to report fo...
TEL AVIV, Israel, Sept. 07, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd . (Nasdaq: PRFX) (" PainReform " or the " Company "), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Company has been selected for a po...
TEL AVIV, Israel, Sept. 05, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (" PainReform " or the " Company "), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer...
American Bio Medica Corp. (ABMC) is expected to report for Q1 2024 Fonar Corporation (FONR) is expected to report for Q1 2024 Bank Hapoalim B.M. ADR (BKHYY) is expected to report for Q2 2023 QualTek Services Inc. (QTEKQ) is expected to report for Q2 2023 BIMI International Medical...
PainReform Ltd. (PRFX) is expected to report for Q2 2023
News, Short Squeeze, Breakout and More Instantly...
PainReform Ltd. Company Name:
PRFX Stock Symbol:
NASDAQ Market:
TEL AVIV, Israel, May 31, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd . (Nasdaq: PRFX) (" PainReform " or the " Company "), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that the Company received a letter from t...
Reaches 50% e nrollment in the s econd p art of its Phase 3 c linical t rial of PRF-110 in b unionectomy Remains on track to announce top-line data i n Q 3 202 4 TEL AVIV, Israel, May 15, 2024 (GLOBE N...
TEL AVIV, Israel, May 08, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (" PainReform " or the " Company "), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer o...